Pacific Therapeutics CEO Provides Updates About Therapy For Idiopathic Pulmonary Fibrosis

Isaura Santos avatar

by Isaura Santos |

Share this article:

Share article via email

shutterstock_217194283Thanks to a partnership with IntelGenx Corp (IGXT), Pacific Therapeutics Ltd. is combining two approved drugs to create a once per day tablet to treat pulmonary fibrosis and other diseases that result from excess scarring.

Pacific Therapeutics is a clinical stage Specialty Pharmaceutical Company that reformulates and reappropriates FDA approved drugs that might have potential to address larger market opportunities and to increase patient compliance and efficacy.

[adrotate group=”4″]

The company’s leading candidate to address fibrosis, with a special focus on Idiopathic Pulmonary Fibrosis (IPF), is PTL-202, which has recently completed its Phase 1 clinical trial. The combination of the drugs revealed a positive interaction that is translated into patients needing lower doses of PTL-202. The combination seems to be more effective than the administration of each component individually when it comes to reducing inflammation and fibrosis in animal models. The patent has already been approved in Europe and is pending in other countries, including the United States.

Pacific is now searching for a partnership that will allow them to develop and commercialize the PTL-202. A Phase 1b dose ranging study of PTL-202 in humans is planned for 2015, which will be followed by a phase 2 concept study for 2016.

[adrotate group=”3″]

Pacific Therapeutics announced that it will continue to be focused on increasing the shareholder base during 2015 and creating value. “Pacific will increase its focus on institutions and funds that focus in the biotech and healthcare industry. In addition, the company will execute a parallel path of stronger fundamentals coupled with a proactive campaign to not only focus on institutional investors but also retail, accredited investors, high net worth family office as well as wall street and industry analysts,” as noted in a press release.

The goal is to accelerate their clinical projects and the licensing of the company’s initiatives that demonstrate potential.

IPF is a disease that results from the accumulation of scar tissue in the air sacs in the lungs, causing a slow suffocation of the patients. The average life expectancy, post diagnosis, is 2.8 years and it has no cure, killing more people than breast or prostate cancer.